Opsoclonus-Myoclonus-Ataxia Syndrome (OMAS) Associated with SARS-CoV-2 Infection: Post-Infectious Neurological Complication with Benign Prognosis

Citations Over TimeTop 11% of 2021 papers

Abstract

The novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) is the cause of the COVID-19 pandemic [5]. SARS-Cov-2 demonstrates partial resemblance to SARS-CoV and MERS-CoV in phylogenetic analysis, clinical manifestations, and pathological findings [6, 7]. Reports emerging from China have described ataxia as a neurological symptom of the SARS-CoV-2 infection [5]. Opsoclonus consists of back-to-back multidirectional conjugate saccades without an inter-saccadic interval [8]. Myoclonus is defined as a sudden, brief, "shock-like", nonepileptic involuntary movement [9], which has been described as a symptom of SARS-CoV-2 infection [10]. Opsoclonus-Myoclonus-Ataxia syndrome (OMAS) associated COVID-19 infection has been reported recently [1112].

Related Papers

• → Delayed, Recurrent Opsoclonus-Myoclonus Syndrome Responding to Plasmapheresis(2005)43 cited
• → Opsoclonus-Myoclonus Syndrome Attributable to Hepatitis C Infection(2010)42 cited
• Opsoclonus myoclonus.(2011)
• → Treatment-refractory paraneoplastic opsoclonus–myoclonus syndrome in a patient with small-cell carcinoma of the lung(2019)3 cited
• Delayed, Recurrent Opsoclonus- Myoclonus Syndrome Responding to(2005)